



## CHARTER LIFE SCIENCES

### Overview

CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital firm that invests primarily in medical device and drug development companies.

CLS plays an active role in helping entrepreneurs build successful companies. The CLS team has a broad range of technical and operational experience that can assist portfolio companies as they progress through early product development and clinical trials to liquidity.

### Investment Strategy

CLS believes that the most dependable and most productive creators of value in life sciences companies are clinical products. Therefore, we invest in product focused early stage companies that use capital efficiently to attain value inflection points and that have a clear path to clinical development.

CLS invests in medical device and drug development companies in roughly equal proportions. CLS typically makes its initial portfolio investment as a leading investor in the first substantial venture capital financing, generally the Series A, and requires board representation. We continue to support our portfolio companies with follow on venture capital investments until they are acquired or go public.

CLS considers investment opportunities located anywhere in the United States and will also consider investment opportunities located outside of the United States, as long as the portfolio company is willing to establish a U.S. based headquarters subsequent to the investment.

### Investment Portfolio

Amaranth Medical, Inc.  
APT Pharmaceuticals, Inc.  
CoMentis, Inc.  
CoRepair, Inc.  
EnteroMedics, Inc. (Nasdaq: ETRM)  
Kereos, Inc.  
KFx Medical Corp.  
Mirabilis Medica, Inc.  
ReVascular Therapeutics Inc.

### Our Team

CLS is managed by a team of professionals with decades of scientific, medical, operational, financial and legal experience. The managing partners have worked together in various capacities for nearly 20 years to build successful life sciences companies.

Managing Partners: A. Barr Dolan  
Donald C. Harrison  
Fred M. Schwarzer  
Nelson Teng

Partner: Gino Di Sciuillo

Chief Financial Officer: Andrew K. Klatt

Professional Staff: Jean L. Kanerva  
Karen E. Morgan

### Scientific and Medical Advisors

Dr. Stanley N. Cohen  
Professor of Genetics and Medicine,  
Stanford University School of Medicine

Dr. Stuart B. Goodman  
Professor of Orthopaedic Surgery,  
Stanford University Medical Center

Dr. Yuet W. Kan  
Professor of Hematology and Chief of  
the Division of Molecular Medicine and  
Diagnostics, University of California,  
San Francisco

Dr. David M. Kipnis  
Professor Emeritus of Molecular  
Biology and Pharmacology, Washington  
University School of Medicine

Dr. James H. Liu  
Chair of the Department of Obstetrics  
and Gynecology, University Hospitals  
Case Medical Center

Dr. Jerrold M. Olefsky  
Dean of Scientific Affairs and Professor  
of Medicine, University of California  
School of Medicine, San Diego Division  
of Endocrinology and Metabolism

Dr. Jerald C. Sadoff  
President & CEO, Aeras Global TB  
Vaccine Foundation